André Rodrigues da Cunha Barreto Vianna

André Rodrigues da Cunha Barreto Vianna

Auto-generated profile, based on publicly available information

André Rodrigues da Cunha Barreto Vianna

Universidade Federal do Paraná, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EFEliete Dalla Corte Frantz
Eliete Dalla Corte Frantz
CCCamila Crespo-Mascarenhas
Camila Crespo-Mascarenhas
ABAndre Rodrigues C. Barreto-Vianna
Andre Rodrigues C. Barreto-Vianna
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
The associations between obesity, hypertension and diabetes are well established, and the renin-angiotensin system (RAS) may provide a link among them. The effect of RAS inhibition on type 2 diabetes is still unclear; however, RAS seems to play an important role in the regulation of the pancreas and glucose intolerance of mice fed high-fat (HF) diet. C57BL/6 mice fed a HF diet (8 weeks) were treated with aliskiren (50 mg/kg/day), enalapril (30 mg/kg/day) or losartan (10 mg/kg/day) for 6 weeks, and the protective effects were extensively compared among groups by morphometry, stereological tools, immunostaining, Western blotting and hormonal analysis. All RAS inhibitors significantly attenuated the increased blood pressure in mice fed a HF diet. Treatment with enalapril, but not aliskiren or losartan, significantly attenuated body mass (BM) gain, glucose intolerance and insulin resistance, improved the alpha and beta cell mass and prevented the reduction of plasma adiponectin. Furthermore, enalapril treatment improved the protein expression of the pancreatic islet Pdx1, GLUT2, ACE2 and Mas receptors. Losartan treatment showed the greatest AT2R expression. Our findings indicate that ACE inhibition with enalapril attenuated several of the deleterious effects of the HF diet. In summary, enalapril appears to be responsible for the normalization of islet morphology and function, of alpha and beta cell mass and of Pdx1 and GLUT2 expression. These protective effects of enalapril were attributed, primarily, to the reduction in body mass gain and food intake and the enhancement of the ACE2/Ang (1-7) /Mas receptor axis and adiponectin levels.

25 February 2016 in Obesity
Verified
Journal Article
Open access
PDF file
ABAndre R.C. Barreto‐Vianna
Andre R.C. Barreto‐Vianna
MAMarcia B. Aguila
Marcia B. Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
Objective: The neuroprotective effects of liraglutide (200 μg/kg, twice daily, subcutaneous administration) in the hypothalamic arcuate nucleus (ARC) of diet‐induced obese mice were investigated.Methods: C57BL/6 mice were separated into groups: standard chow treated with vehicle or liraglutide and the respective liraglutide pair‐fed group; high‐fat diet treated with vehicle or liraglutide and the respective pair‐fed group. Body mass (BM) evolution, carbohydrate metabolism, leptin resistance, proteins involved in energetic balance, apoptosis, and microglia in the ARC were studied.Results: Obese animals showed glucose intolerance, resistance to insulin and to anorexigenic effect of leptin, and microgliosis accompanied by elevated Bax/Bcl2 ratio in the ARC. Liraglutide improved the carbohydrate metabolism, BM loss, and the activation of pro‐opiomelanocortin (POMC) and cocaine and amphetamine‐regulated transcript (CART) in the ARC. The liraglutide enhanced leptin sensitivity and diminished the microgliosis with decrease in Bax/Bcl2 ratio.Conclusions: Liraglutide activates central anorexigenic pathways, thereby diminishing the energy intake of obese mice and improving the metabolic parameters related to obesity. Liraglutide is a relevant neuroprotective agent, which can decrease the microgliosis and stimulate the anti‐apoptotic pathway, a significant effect in the treatment of obesity and its comorbidities. Some benefits of liraglutide are independent of the BM loss, which usually accompanies the drug administration.

5 July 2017 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
ABAndre R. C. Barreto-Vianna
Andre R. C. Barreto-Vianna
MAMarcia B. Aguila
Marcia B. Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda

3 May 2016 in Endocrine
Verified
Journal Article
Closed access
PDF file
TMThais C. Maia-Ceciliano
Thais C. Maia-Ceciliano
ABAndre R. C. Barreto-Vianna
Andre R. C. Barreto-Vianna
SBSandra Barbosa-Da-Silva
Sandra Barbosa-Da-Silva
MAMarcia B. Aguila
Marcia B. Aguila
TFTatiane S. Faria
Tatiane S. Faria
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda

1 January 2018 in Journal of Experimental Orthopaedics
Verified
Journal Article
Open access
PDF file
CSClarissa Rocha dos Santos
Clarissa Rocha dos Santos
RFRichard da Rocha Filgueiras
Richard da Rocha Filgueiras
PMPatrícia Furtado Malard
Patrícia Furtado Malard
ABAndre Rodrigues da Cunha Barreto‐Vianna
Andre Rodrigues da Cunha Barreto‐Vianna
KNKaique Nogueira
Kaique Nogueira
ELEduardo Maurício Mendes De Lima
Eduardo Maurício Mendes De Lima
Background: The cranial cruciate ligament rupture (CCLR) is the most commonly encountered orthopedic condition in dogs. Among the various techniques to treat this condition, tibial tuberosity advancement (TTA) has been used to obtain rapid recovery of the affected knee. The objective of this study was to evaluate the viability of the use of mesenchymal stem cells (MSC) implanted in the osteotomy site obtained by TTA in nine dogs diagnosed with CCLR.Methods: The MSC were isolated from the adipose tissue of the dogs and cultured for eight days, the animals were divided into two groups. Animals from the treated group (GT) received cell transport medium containing about 1.5 millions MSC, and the animals from the control group (GC) received only the cell transport medium. The study was performed in a double‐blind manner using radiographs acquired on days 15, 30, 60 and 120 after the procedure. Evaluations of the density of the trabecular bone were performed using image analysis software. The results were subjected to descriptive statistical analysis, followed by the normality test, Chi‐square test, Mann‐Whitney test and Tukey’s multiple comparison test for p ≤ 0.05.Results: After 30 days of the procedure, the animals of the GT presented an ossification mean 36.45% greater (p ≤ 0.033) than the GC, and there were no statistical differences for the other periods.Conclusions: Despite the total bone ossification within the expected period, there was no minimization of the estimated recovery time with the application of MSC, and inflammatory factors should be considered for reassessment of the therapeutic intervention time.

21 January 2015 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
LHLucio N. Huaixan
Lucio N. Huaixan
SASilvana S. B. Arruda
Silvana S. B. Arruda
ALAndré S. Leonardo
André S. Leonardo
JVJaniny C. Viana
Janiny C. Viana
ABAndré R. C. Barreto‐Vianna
André R. C. Barreto‐Vianna
ELEduardo Maurício Mendes De Lima
Eduardo Maurício Mendes De Lima